Reported results
- Revenue of $7.2 million for the third quarter of 2026, up 125% from $3.2 million in the second quarter of 2026.
- Operating income of $6.8 million for the third quarter of 2026.
- Net income of $11.5 million, or $0.52 per common share on a diluted basis, for the third quarter of 2026.
- Adjusted EBITDA of approximately ($2.3 million) for the third quarter of 2026.
- Cash and cash equivalents of $147.7 million as of September 30, 2026.
Notes
Helomics business was sold and is reported as discontinued operations; results for prior periods have been recast to remove the legacy business.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-17 (8-K, Item 2.02). Read the original filing on sec.gov.
